Akebia Has Affirmed Its 2023 Auryxia Net Product Revenue Guidance Of $175M-$180M
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has confirmed its 2023 net product revenue guidance for Auryxia, expecting it to be between $175M-$180M.
August 25, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics has reaffirmed its 2023 net product revenue guidance for Auryxia, which is expected to be between $175M-$180M.
Akebia Therapeutics' reaffirmation of its 2023 net product revenue guidance for Auryxia indicates a positive outlook for the company's financial performance. This could potentially lead to an increase in investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100